We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+35.97%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$343M
Cap. Flow
+$210M
Cap. Flow %
19.51%
Top 10 Hldgs %
30.46%
Holding
99
New
30
Increased
28
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$29M
2
INSM icon
Insmed
INSM
+$26.6M
3
HUM icon
Humana
HUM
+$22.7M
4
CYTK icon
Cytokinetics
CYTK
+$19.3M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$15.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$19.9M
2
TFX icon
Teleflex
TFX
+$17.5M
3
NTRA icon
Natera
NTRA
+$13.2M
4
ZBH icon
Zimmer Biomet
ZBH
+$12.2M
5
LLY icon
Eli Lilly
LLY
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVH icon
51
Evolent Health
EVH
$464M
$8.2M 0.76%
250,000
– –
TNDM icon
52
Tandem Diabetes Care
TNDM
$1.63B
$7.97M 0.74%
+225,000
New +$6.03M
FDMT icon
53
4D Molecular Therapeutics
FDMT
$600M
$7.96M 0.74%
250,000
-125,000
-33% -$3.19M
ALNY icon
54
Alnylam Pharmaceuticals
ALNY
$29.6B
$7.47M 0.69%
50,000
+5,000
+11% +$834K
OSCR icon
55
Oscar Health
OSCR
$8.63B
$7.43M 0.69%
+500,000
New +$6.85M
MRUS
56
DELISTED
Merus
MRUS
$7.43M 0.69%
+165,000
New +$6.69M
MGNX icon
57
MacroGenics
MGNX
$249M
$7.36M 0.68%
500,000
+50,000
+11% +$756K
CABA icon
58
Cabaletta Bio
CABA
$455M
$7.25M 0.67%
425,000
-95,000
-18% -$2.04M
INSP icon
59
Inspire Medical Systems
INSP
$1.71B
$7.09M 0.66%
33,000
-27,000
-45% -$5.29M
ALKS icon
60
Alkermes
ALKS
$8.26B
$6.77M 0.63%
250,000
+1,000
+0.4% +$28.4K
ROIV icon
61
Roivant Sciences
ROIV
$25.5B
$6.32M 0.59%
+600,000
New +$6.47M
ONC
62
BeOne Medicines Ltd
ONC
$40.6B
$6.26M 0.58%
+40,000
New +$6.44M
RLAY icon
63
Relay Therapeutics
RLAY
$4.38B
$6.02M 0.56%
725,000
+125,000
+21% +$1.22M
SRRK icon
64
Scholar Rock
SRRK
$6.34B
$5.77M 0.54%
325,000
+225,000
+225% +$3.54M
RVTY icon
65
Revvity
RVTY
$12.9B
$5.25M 0.49%
+50,000
New +$5.32M
ALGN icon
66
Align Technology
ALGN
$12.3B
$4.92M 0.46%
15,000
-15,000
-50% -$4.4M
NTRA icon
67
Natera
NTRA
$45.1B
$4.57M 0.42%
50,000
-175,000
-78% -$13.2M
LH icon
68
Labcorp
LH
$26.1B
$4.37M 0.41%
20,000
-30,000
-60% -$6.61M
A icon
69
Agilent Technologies
A
$42.2B
$4.37M 0.41%
+30,000
New +$4.11M
SYRE icon
70
Spyre Therapeutics
SYRE
$9.06B
$3.79M 0.35%
+100,000
New +$2.9M
SAGE
71
DELISTED
Sage Therapeutics
SAGE
$3.75M 0.35%
200,000
– –
ETNB
72
DELISTED
89bio
ETNB
$3.49M 0.32%
+300,000
New +$3.32M
EDIT icon
73
Editas Medicine
EDIT
$453M
$3.34M 0.31%
+450,000
New +$3.74M
AUTL
74
Autolus Therapeutics
AUTL
$620M
$3.19M 0.3%
+500,000
New +$3.12M
MREO
75
Mereo BioPharma
MREO
$48.8M
$3.13M 0.29%
+950,000
New +$3.22M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Integral Health Asset Management held 99 positions worth $1.08B, up 47% from $734M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Integral Health Asset Management deployed $210M of net new capital in Q1 2024, opening 30 new positions and adding to 28 existing holdings. Its largest new stake was Merck: 235,000 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $13.2M trimmed.

  • Integral Health Asset Management's largest Q1 2024 buy was Merck: 235,000 shares worth $31M.
  • Integral Health Asset Management added most to Insmed in Q1 2024, an estimated $26.6M increase.
  • Integral Health Asset Management's biggest Q1 2024 reduction was Natera, cutting an estimated $13.2M.
  • Integral Health Asset Management fully exited Sanofi in Q1 2024, selling an estimated $19.9M.
  • Integral Health Asset Management's ten largest holdings make up 30% of its $1.08B portfolio in Q1 2024.
  • Integral Health Asset Management opened 30 new positions and closed 19 in Q1 2024.
  • Integral Health Asset Management's portfolio value rose 47% quarter-over-quarter to $1.08B.

Based on Integral Health Asset Management's 13F filing for Q1 2024, filed 15 May 2024.